DC Chemicals · Product datasheet

Fexaramine — Datasheet

CAT. NO. DC8085

Product page and current package options

ParameterValue
Chemical NameFexaramine
CAS No.574013-66-4
Synonyms2-Propenoic acid,3-[3-[(cyclohexylcarbonyl)[[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-,methyl ester;2-Propenoic acid,3-[3-[(cyclohexylcarbonyl)[[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]methyl]ami...;3-[3-[(Cyclohexylcarbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoicacidmethylester;Fexaramine;Fexaramine,3-[3-[(Cyclohexylcarbonyl)-[[4'-(dimethylamino)-[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoicacidmethylester;3-[3-[(Cyclohexylcarbonyl)[[4′-(dimethylamino)[1,1′-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoic acid methyl ester;(2E)-3-[3-[(Cyclohexylcarbonyl)[[4'-(dimethylamino)[1,1'-biphenyl]-4-yl]methyl]amino]phenyl]-2-propenoic acid methyl ester;FEX;(E)-methyl 3-(3-(N-((4'-(dimethylamino)-[1,1'-biphenyl]-4-yl)methyl)cyclohexanecarboxamido)phenyl)acrylate;C32H36N2O3;GTPL2744;Fexaramine, >=98% (HPLC);AOB5017;HMS3413H09;HMS3677H09;BCP15784;3671AH;BDBM50167161;DB02545;BC600742;AK175872;B7108;C15649;(E)-3-{3-[Cyclohexanecarbonyl-(4''-di
FormulaC32H36N2O3
M.Wt496.6398
SMILESO=C(C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H])N(C1=C([H])C([H])=C([H])C(/C(/[H])=C(\[H])/C(=O)OC([H])([H])[H])=C1[H])C([H])([H])C1C([H])=C([H])C(C2C([H])=C([H])C(=C([H])C=2[H])N(C([H])([H])[H])C([H])([H])[H])=C([H])C=1[H]
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Fexaramine is a small molecule farnesoid X receptor (FXR) agonist with 100-fold increased affinity relative to natural compounds. IC50 value:Target:in vitro: In vitro treatment of CDCA or fexaramine elevated the SHP transcript level and occupancy on secretin promoter [1]. Fexaramine significantly enhanced osteoblastic differentiation through the upregulation of Runx2 and enhanced extracellular signal-regulated kinase (ERK) and β-catenin signaling [2]. By mimicking this tissue-selective effect, the gut-restricted FXR agonist fexaramine (Fex) robustly induces enteric fibroblast growth factor 15 (FGF15), leading to alterations in BA composition, but does so without activating FXR target genes in the liver [3].

In Vitro

No in vitro data are provided in the current product source. Contact us for further information.

In Vivo

No in vivo data are provided in the current product source. Contact us for further information.

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Cart

Request quotation